121 related articles for article (PubMed ID: 37327205)
21. Identification of a novel germline missense mutation of the androgen receptor in African American men with familial prostate cancer.
Hu SY; Liu T; Liu ZZ; Ledet E; Velasco-Gonzalez C; Mandal DM; Koochekpour S
Asian J Androl; 2010 May; 12(3):336-43. PubMed ID: 20173765
[TBL] [Abstract][Full Text] [Related]
22. The Mutational and Transcriptional Landscapes of Speckle-Type POZ Protein (SPOP) and Androgen Receptor (AR) in a Single-Center pT3 Prostatectomy Cohort.
Eryilmaz IE; Vuruskan BA; Kaygisiz O; Cecener G; Egeli U; Vuruskan H
J Environ Pathol Toxicol Oncol; 2024; 43(1):15-29. PubMed ID: 37824367
[TBL] [Abstract][Full Text] [Related]
23. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer.
Swami U; Isaacsson Velho P; Nussenzveig R; Chipman J; Sacristan Santos V; Erickson S; Dharmaraj D; Alva AS; Vaishampayan UN; Esther J; Hahn AW; Maughan BL; Antonarakis ES; Agarwal N
Eur Urol; 2020 Nov; 78(5):652-656. PubMed ID: 32624276
[TBL] [Abstract][Full Text] [Related]
24. SPOP-mutant prostate cancer: Translating fundamental biology into patient care.
Bernasocchi T; Theurillat JP
Cancer Lett; 2022 Mar; 529():11-18. PubMed ID: 34974131
[TBL] [Abstract][Full Text] [Related]
25. Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
Stangl A; Wilner C; Li P; Maahs L; Hwang C; Pilling A
Prostate; 2023 May; 83(6):524-533. PubMed ID: 36604824
[TBL] [Abstract][Full Text] [Related]
26. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
[TBL] [Abstract][Full Text] [Related]
27. SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.
Swami U; Graf RP; Nussenzveig RH; Fisher V; Tukachinsky H; Schrock AB; Li G; Ross JS; Sayegh N; Tripathi N; Mathew Thomas V; Oxnard GR; Antonarakis ES; Agarwal N
Clin Cancer Res; 2022 Nov; 28(22):4917-4925. PubMed ID: 36088616
[TBL] [Abstract][Full Text] [Related]
28. Risk Stratification of Prostatic Adenocarcinoma Metastatic to the Lymph Nodes.
Bidot S; Monsrud A; Kline M; Speak A; Martini D; Bilen MA; Switchenko JM; Zhang Y; Gerges AG; Farhat GN; Dent EA; Master VA; Tinsley ML; Harik LR
Arch Pathol Lab Med; 2022 Nov; 146(11):1345-1352. PubMed ID: 35142822
[TBL] [Abstract][Full Text] [Related]
29. Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer.
García-Flores M; Casanova-Salas I; Rubio-Briones J; Calatrava A; Domínguez-Escrig J; Rubio L; Ramírez-Backhaus M; Fernández-Serra A; García-Casado Z; López-Guerrero JA
Eur J Cancer; 2014 Nov; 50(17):2994-3002. PubMed ID: 25204806
[TBL] [Abstract][Full Text] [Related]
30. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
Nizialek E; Lim SJ; Wang H; Isaacsson Velho P; Yegnasubramanian S; Antonarakis ES
Prostate; 2021 Jun; 81(9):572-579. PubMed ID: 33955569
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of the SPOP mutant genomic subclass in prostate cancer.
Shoag J; Liu D; Ma X; Oromendia C; Christos P; Ballman K; Angulo C; Cai PY; Gaffney C; Klein E; Karnes J; Den RB; Liu Y; Davicioni E; Barbieri CE
Urol Oncol; 2020 May; 38(5):418-422. PubMed ID: 32192889
[TBL] [Abstract][Full Text] [Related]
32. TP53, SPOP and PIK3CA Genes Status in Prostate Cancer.
Al Zoubi MS; Otoum R; Alorjani MS; Al Bashir S; Al Trad B; Abualrja MI; Al-Khatib SM; Al-Batayneh K
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3365-3371. PubMed ID: 33247697
[TBL] [Abstract][Full Text] [Related]
33. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.
Boysen G; Rodrigues DN; Rescigno P; Seed G; Dolling D; Riisnaes R; Crespo M; Zafeiriou Z; Sumanasuriya S; Bianchini D; Hunt J; Moloney D; Perez-Lopez R; Tunariu N; Miranda S; Figueiredo I; Ferreira A; Christova R; Gil V; Aziz S; Bertan C; de Oliveira FM; Atkin M; Clarke M; Goodall J; Sharp A; MacDonald T; Rubin MA; Yuan W; Barbieri CE; Carreira S; Mateo J; de Bono JS
Clin Cancer Res; 2018 Nov; 24(22):5585-5593. PubMed ID: 30068710
[No Abstract] [Full Text] [Related]
34. Squamous Transformation of Prostate Adenocarcinoma: A Report of Two Cases With Genomic Profiling.
Dizman N; Salgia M; Ali SM; Wu H; Arvanitis L; Chung JH; Pal SK
Clin Genitourin Cancer; 2020 Jun; 18(3):e289-e292. PubMed ID: 31882336
[No Abstract] [Full Text] [Related]
35. Mid-term oncologic outcomes of radical prostatectomy in lymph node metastatic prostate cancer patients.
Berchiche W; Long Depaquit T; Baboudjian M; Barret É; Rozet F; Cathelineau X; Bastide C
Prog Urol; 2023 Aug; 33(8-9):437-445. PubMed ID: 37248105
[TBL] [Abstract][Full Text] [Related]
36. SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression.
Geng C; Zhang MC; Manyam GC; Vykoukal JV; Fahrmann JF; Peng S; Wu C; Park S; Kondraganti S; Wang D; Robinson BD; Loda M; Barbieri CE; Yap TA; Corn PG; Hanash S; Broom BM; Pilié PG; Thompson TC
Clin Cancer Res; 2023 Nov; 29(21):4464-4478. PubMed ID: 37581614
[TBL] [Abstract][Full Text] [Related]
37. Risk of lymph node metastases in pathological gleason score≤6 prostate adenocarcinoma: Analysis of institutional and population-based databases.
Wenger H; Weiner AB; Razmaria A; Paner GP; Eggener SE
Urol Oncol; 2017 Jan; 35(1):31.e1-31.e6. PubMed ID: 27692833
[TBL] [Abstract][Full Text] [Related]
38. SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
Luo Z; Wang J; Zhu Y; Sun X; He C; Cai M; Ma J; Wang Y; Han S
Neoplasia; 2021 Oct; 23(10):1037-1047. PubMed ID: 34509929
[TBL] [Abstract][Full Text] [Related]
39. Identification of speckle-type POZ protein somatic mutations in African American prostate cancer.
Buckles E; Qian C; Tadros A; Majumdar S; Cvitanovic J; Zabaleta J; Estrada J; Wilson J; Liu W
Asian J Androl; 2014; 16(6):829-32. PubMed ID: 24994784
[TBL] [Abstract][Full Text] [Related]
40. Deregulation of SPOP in Cancer.
Zhang H; Jin X; Huang H
Cancer Res; 2023 Feb; 83(4):489-499. PubMed ID: 36512624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
